Predictors of early mortality risk in patients with epithelial ovarian cancer

Abstract

Background To improve the overall survival of epithelial ovarian cancer (EOC) patients, a more precise risk identification after completion of standard treatment will enhance patients' follow‐up surveillance and the use of individualized targeted therapy. Aim This study explored the potential risk predictors of early mortality in EOC patients who had standard treatment with debulking surgery and chemotherapy. Methods The study included 93 EOC patients who had standard treatment and were followed up between January 2011 and December 2020. The sociodemographic, clinical, and laboratory data of patients with EOC including the update on their 3‐year follow‐up status were retrospectively collected and analyzed. Early mortality is defined as the death of a patient within 3 years of completion of standard treatment. Patients' data were computed using descriptive statistics and the associations between patients' factors and the risk of early mortality were tested using the binary logistic regression model. Results Early deaths occurred in 36 (38.7%) of patients with EOC. In the final multivariate analyses, early tumor relapse within 6‐months of treatment completion was the only independent risk factor that predicts early mortality in EOC patients (risk ratio = 8.6, 95% confidence interval: 3.3–24.5, p < 0.01). Conclusion Our study suggests that early tumor relapse may be a useful surrogate of early mortality in EOC. However, our findings should be interpreted with caution pending further corroboration through an adequately powered, prospective multicenter study.

Survival outcomes following interval versus primary debulking surgery in advanced epithelial ovarian cancer: A retrospective cohort study in Lagos, Southwest Nigeria

“…The hospital’s gynaecologic oncology unit comprising four consultant gynaecologic oncologists and up to 15 resident doctors provides various in-patient and out-patient multidisciplinary oncology services including the screening and treatment of different premalignant and malignant diseases of the female genital tract. 16 …”

Epithelial Membrane Protein 1 is a Potential Prognostic Biomarker for Ovarian Cancer

“…Ovarian cancer is the most common tumour type of the female reproductive system and has a high mortality rate [1,2] due to the usually advanced stage at diagnosis [3]. Conventional treatment of ovarian cancer involves surgery followed by chemotherapy with platinum and paclitaxel.…”

Prognostic Performance of Pretreatment Systemic Immune-Inflammation Index in Women with Epithelial Ovarian Cancer

“…The epithelial histotypes (EOC) account for more than 90% of all ovarian cancer [ 1 , 3 ] with more than 70% of these diagnosed at a later stage of the disease [ 4 ] when it is characterized by poor survival prognosis [ 5 ]. A risk-stratification strategy using patient- and tumor-specific characteristics is now being proposed to predict survival and to identify EOC patients who require more intensive treatment and individualized follow-up surveillance plans [ 6 ]. This is especially more important in resource-limited settings such as Nigeria with much higher mortality seen as patients advance through the disease trajectory [ 4 ].…”